CX-717

CX-717 is an ampakine compound drug developed by Cortex Pharmaceuticals. It has been proposed as a treatment for Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), schizophrenia, and sleep deprivation.

History

CX-717 was developed by Cortex Pharmaceuticals as part of their research into ampakine drugs. Ampakines are a class of compounds known to enhance glutamate transmission in the brain. They are being investigated for their potential to improve cognition and behavior in diseases such as Alzheimer's disease, ADHD, and schizophrenia.

Mechanism of Action

CX-717 is an ampakine drug, which means it works by enhancing the action of the neurotransmitter glutamate at AMPA receptors. These receptors are a type of ionotropic glutamate receptor, mediating fast synaptic transmission in the central nervous system. By enhancing the action of glutamate at these receptors, CX-717 is thought to improve cognition and behavior.

Clinical Trials

CX-717 has been tested in several clinical trials. In 2006, the U.S. Food and Drug Administration (FDA) placed a clinical hold on the drug, citing preclinical toxicology studies. However, the hold was lifted later that year, and clinical trials have continued.

Potential Uses

CX-717 has been proposed as a treatment for several conditions, including Alzheimer's disease, ADHD, schizophrenia, and sleep deprivation. However, more research is needed to confirm its efficacy and safety in these conditions.

See Also

• Ampakine
• Glutamate
• AMPA receptor
• Alzheimer's disease
• Attention deficit hyperactivity disorder
• Schizophrenia
• Sleep deprivation

CX-717 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia